Aspen Pharmacare Holdings Ltd
JSE:APN
Relative Value
There is not enough data to reliably calculate the relative value of APN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
APN Competitors Multiples
Aspen Pharmacare Holdings Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
ZA |
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
100.9B Zac | 0 | 0 | 0 | 0 | |
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
697.9B USD | 20.5 | 133.2 | 60.2 | 69.1 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.3 | 45.2 | 33 | 36 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
357.8B USD | 4.4 | 8.8 | 11.8 | 15.5 | ||
US |
Merck & Co Inc
NYSE:MRK
|
323.8B USD | 5.3 | 140.4 | 33.4 | 53 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.3 | 140.6 | 225.6 | ||
CH |
Novartis AG
SIX:NOVN
|
179.8B CHF | 4.2 | 13.3 | 9.7 | 16.1 | ||
CH |
Roche Holding AG
SIX:ROG
|
172.7B CHF | 2.9 | 15 | 8.6 | 10.2 | ||
US |
Pfizer Inc
NYSE:PFE
|
155.7B USD | 2.7 | 73.5 | 11 | 16.2 |